[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA94335B - 2,6-Diaminopurine derivatives. - Google Patents

2,6-Diaminopurine derivatives.

Info

Publication number
ZA94335B
ZA94335B ZA94335A ZA94335A ZA94335B ZA 94335 B ZA94335 B ZA 94335B ZA 94335 A ZA94335 A ZA 94335A ZA 94335 A ZA94335 A ZA 94335A ZA 94335 B ZA94335 B ZA 94335B
Authority
ZA
South Africa
Prior art keywords
diaminopurine derivatives
diaminopurine
derivatives
Prior art date
Application number
ZA94335A
Other languages
English (en)
Inventor
Michael Gregson
Barry Edward Ayres
George Blanch Ewan
Frank Ellis
John Knight
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA94335B publication Critical patent/ZA94335B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA94335A 1993-01-20 1994-01-18 2,6-Diaminopurine derivatives. ZA94335B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939301000A GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds

Publications (1)

Publication Number Publication Date
ZA94335B true ZA94335B (en) 1994-10-24

Family

ID=10728948

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94335A ZA94335B (en) 1993-01-20 1994-01-18 2,6-Diaminopurine derivatives.

Country Status (29)

Country Link
US (2) US5925624A (de)
EP (1) EP0680488B1 (de)
JP (1) JP3768232B2 (de)
KR (1) KR960700261A (de)
CN (1) CN1043997C (de)
AP (1) AP457A (de)
AT (1) ATE164849T1 (de)
AU (1) AU679714B2 (de)
CA (1) CA2153688A1 (de)
CZ (1) CZ187995A3 (de)
DE (1) DE69409503T2 (de)
DK (1) DK0680488T3 (de)
EC (1) ECSP941104A (de)
ES (1) ES2117249T3 (de)
FI (1) FI953489A (de)
GB (1) GB9301000D0 (de)
HU (1) HU211914A9 (de)
IL (1) IL108372A (de)
IS (1) IS4121A (de)
NO (1) NO305603B1 (de)
NZ (1) NZ259880A (de)
PE (1) PE54194A1 (de)
PL (1) PL309975A1 (de)
RU (1) RU2129561C1 (de)
SI (1) SI9400021A (de)
SK (1) SK281229B6 (de)
TW (1) TW267168B (de)
WO (1) WO1994017090A1 (de)
ZA (1) ZA94335B (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO119414B1 (ro) * 1995-05-30 2004-10-29 Rhone-Poulenc Rorer S.A. Derivaţi de 2-azabiciclo[2.2.1]heptan, procedee de preparare şi intermediari pentru acestea
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3861413B2 (ja) * 1997-11-05 2006-12-20 ソニー株式会社 情報配信システム、情報処理端末装置、携帯端末装置
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
BR9908325A (pt) * 1998-02-26 2000-11-07 Aventis Pharma Inc 6 9-dissubstituìdo 2-[trans-4(4-aminociclohexil)amino]purinas
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
DZ2805A1 (fr) 1998-06-02 2005-01-30 Cadus Pharmaceutical Corp Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages.
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7115589B2 (en) 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
WO2001081346A2 (en) 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1939203B1 (de) * 2000-04-25 2014-11-19 ICOS Corporation Hemmer der delta-Isoform der menschlichen Phosphatidyl-Inositol-3-Kinase
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
CA2451738C (en) * 2001-07-06 2013-09-17 Topigen Pharmaceutique Inc. Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
ES2333945T3 (es) 2001-11-27 2010-03-03 Anadys Pharmaceuticals, Inc. Nucleosidos de 3-beta-d-ribofurano-siltiazolo(4,5-delta)pirimidina y usos de los mismos.
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
ES2237234B1 (es) * 2002-08-02 2006-11-01 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0328319D0 (en) * 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Improved synthesis of 2-substituted adenosines
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP1758596B9 (de) * 2004-05-26 2010-09-15 Inotek Pharmaceuticals Corporation Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
FR2874014B1 (fr) * 2004-08-03 2010-05-14 Univ Paris Descartes Analogues d'aminoglycosides, leur utilisation et leur synthese
AU2005299218B2 (en) * 2004-10-29 2012-04-12 Pharmaxis Ltd Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
ES2459368T3 (es) 2004-12-17 2014-05-09 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
BRPI0617485B8 (pt) 2005-10-21 2021-05-25 Novartis Ag anticorpo anti-il-13 humano isolado, composição farmacêutica e uso do referido anticorpo
SG152296A1 (en) 2005-11-21 2009-05-29 Anadys Pharmaceuticals Inc Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MX2008016518A (es) 2006-06-22 2009-01-19 Anadys Pharmaceuticals Inc Profarmacos de 5-amino-3-(3'-desoxi-beta-d-ribofuranosil)-tiazolo[ 4,5-d]pirimidin-2,7-dion.
DE602007012881D1 (en) 2006-07-18 2011-04-14 Anadys Pharmaceuticals Inc Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
US8796241B2 (en) 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
ES2331867B1 (es) * 2008-07-17 2010-10-27 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.
US20100202963A1 (en) 2008-11-13 2010-08-12 Gallatin W Michael Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
AU2010239312A1 (en) 2009-04-20 2011-11-10 Gilead Calistoga Llc Methods of treatment for solid tumors
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
MX2012008049A (es) 2010-01-12 2012-08-01 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
ES2551592T3 (es) 2011-02-25 2015-11-20 Novartis Ag Pirazolo[1,5-a]piridinas como inhibidores de TRK
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
TW201350486A (zh) 2012-03-05 2013-12-16 Gilead Calistoga Llc （ｓ）－２－（１－（９ｈ－嘌呤－６－基胺基）丙基）－５－氟－３－苯基喹唑啉－４（３ｈ）－酮的多晶型
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
KR101770048B1 (ko) 2012-12-21 2017-08-21 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
EP3252058B1 (de) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclische carbamoylpyridonverbindungen und deren verwendung zur behandlung von hiv-infektionen
NO2865735T3 (de) 2013-07-12 2018-07-21
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EA201690990A1 (ru) 2013-12-20 2016-11-30 Джилид Калистога Ллс Способы получения ингибиторов фосфатидилинозитол-3-киназы
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
NO2717902T3 (de) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
WO2018030184A1 (ja) * 2016-08-10 2018-02-15 株式会社スリーボンド エポキシ樹脂組成物およびこれを含む導電性接着剤
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
CA1239397A (en) * 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
EP0300144A3 (de) * 1984-04-18 1989-09-27 Whitby Research Incorporated N-6-Alkyl substituierte Adenosinderivate als herzwirksame Vasodilatoren
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4757747A (en) * 1986-04-08 1988-07-19 Vickers, Incorporated Power transmission
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
FI880405A (fi) * 1987-02-04 1988-08-05 Ciba Geigy Ag Adenosin-5'-karboxamidderivat.
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
DE68924319T2 (de) * 1988-03-16 1996-05-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
CA2028002A1 (en) * 1989-10-19 1991-04-20 Daniel P. Becker Method of treating gastrointestinal motility disorders
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
DE4025879A1 (de) * 1990-08-16 1992-02-20 Sandoz Ag Neue adenosin derivate, deren herstellung und verwendung
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists

Also Published As

Publication number Publication date
SK91895A3 (en) 1996-04-03
KR960700261A (ko) 1996-01-19
US5925624A (en) 1999-07-20
FI953489A0 (fi) 1995-07-19
DE69409503T2 (de) 1998-08-06
JPH08505864A (ja) 1996-06-25
ECSP941104A (es) 1994-12-15
EP0680488A1 (de) 1995-11-08
ES2117249T3 (es) 1998-08-01
PE54194A1 (es) 1995-01-06
JP3768232B2 (ja) 2006-04-19
WO1994017090A1 (en) 1994-08-04
ATE164849T1 (de) 1998-04-15
IL108372A0 (en) 1994-04-12
NO952872L (no) 1995-09-13
NO952872D0 (no) 1995-07-19
IL108372A (en) 1998-06-15
SK281229B6 (sk) 2001-01-18
SI9400021A (en) 1994-09-30
DE69409503D1 (de) 1998-05-14
FI953489A (fi) 1995-09-13
AU5885194A (en) 1994-08-15
US5889178A (en) 1999-03-30
HU211914A9 (en) 1996-01-29
AP457A (en) 1996-02-01
TW267168B (de) 1996-01-01
IS4121A (is) 1994-07-21
GB9301000D0 (en) 1993-03-10
CN1043997C (zh) 1999-07-07
CA2153688A1 (en) 1994-08-04
CZ187995A3 (en) 1996-01-17
RU2129561C1 (ru) 1999-04-27
NZ259880A (en) 1996-11-26
DK0680488T3 (da) 1999-01-25
PL309975A1 (en) 1995-11-13
AP9400613A0 (en) 1994-01-31
AU679714B2 (en) 1997-07-10
CN1119440A (zh) 1996-03-27
EP0680488B1 (de) 1998-04-08
NO305603B1 (no) 1999-06-28

Similar Documents

Publication Publication Date Title
ZA94335B (en) 2,6-Diaminopurine derivatives.
DE59403259D1 (en) Tetraaroxyperylen-3,4,9,10-tetracarbonsäurepolyimide
GR3029455T3 (en) 3-Aryl-4-hydroxy-3-dihydrofuranone derivatives.
ZA926733B (en) 1,2-Dihydro-2-oxopyridines.
PH30894A (en) 1,5-Benzodiazepine derivative.
DE58908138D1 (en) 2,3-difluorbenzole.
DE58905134D1 (en) 2,3-difluorbiphenyle.
ZA941137B (en) Substitutet azolone derivatives.
GR3030863T3 (en) 2',5'-oligoadenylate-2',3'-cyclophosphates
ZA945238B (en) 1,5 Benzodiazepine derivatives.
ZA946569B (en) 1,5-Diphenyl-3-pyrazolylalkyl-N-hydroxydithiocarbamates
EP0710107A4 (de) N,n,n-trimethylsphingosin-derivate
HK1003005A1 (en) 2,4-Dimethyl-6-s-alkyl-phenols 2 ' 4.
DE68913498D1 (en) 1,1-dioxo-cephem-4-carbothiolsäure-derivate.
HU9400745D0 (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives
ZA934381B (en) Phenyl-1,2,5-oxadiazolecarboxamide-2-oxides.
OA09719A (en) 1,4-Diamino-2,3-Dihydroxybutanes.
ZA942880B (en) 2,6.disubstituted 4-quinolyl-dihydropridines
HU9301651D0 (en) Pyridyl-1,2,5-oxadiazole-carbonamide-2-oxide derivatives
HK1002589A1 (en) 2,3-Dihydrobenzofuran derivatives
EP0657435A3 (de) 1,2-Dihydro-2-oxo-pyridine.
IL110556A0 (en) 7 alpha-amino-1, 1-dioxocephem l- valylamides
HU9402902D0 (en) 1,2-dihydro-2-oxo-3-methyl-sulfonyl-aminomethyl-pyridine derivatives
ZA941763B (en) Carpaine derivatives.
EP0683787A1 (de) 4'-0-sulfonylanthracyclinderivate.